A phase III open-label, comparative, multicentre trials to test the concept of durable virologic suppression in subjects with primary HIV-1 infection after intensive induction of quadruple HAART followed by double-blind randomization to HIV vaccination wi

×

Foutmelding

  • Notice: Trying to access array offset on value of type null in bootstrap_pager() (regel 53 van /var/www/biosafety.be/sites/all/themes/bootstrap/templates/system/pager.func.php).
  • Notice: Trying to access array offset on value of type null in bootstrap_pager() (regel 95 van /var/www/biosafety.be/sites/all/themes/bootstrap/templates/system/pager.func.php).
Study title: 
A phase III open-label, comparative, multicentre trials to test the concept of durable virologic suppression in subjects with primary HIV-1 infection after intensive induction of quadruple HAART followed by double-blind randomization to HIV vaccination wi
Long title: 
A phase III open-label, comparative, multicentre trials to test the concept of durable virologic suppression in subjects with primary HIV-1 infection after intensive induction of quadruple HAART followed by double-blind randomization to HIV vaccination with ALVAC-HIV (vCP-1452) and Remune or placebo while maintaining optimal therapeutic viral suppression
Date receipt dossier: 
13 okt 2000
Pharmaceutical study code: 
PROB3005
Company / Sponsor: 
Glaxo Wellcome
Phase: 
III
Treated organism: 
Humans
Indication category: 
Infectious disease
Disease: 
AIDS
Therapeutic approach: 
Immunotherapy
Genetic modification: 
vCP-1452
Method of transfer of nucleic acid of interest: 
Attenuated Canarypox Virus (ALVAC)
Administered biological material: 
Recombinant Canarypox Virus
Route of administration: 
Intramuscular
Locations in Belgium: 
Centre Hospitalier Universitaire St Pierre, Brussels
Type of procedure: 
Contained use only
Notes: 
Sponsor of the study: Glaxo Wellcome; Manufacturer of the GMO: Aventis-Pasteur S.A.